Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

FORMA THERAPEUTICS HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation FD Disclosure (form 8-K)

06/14/2021 | 07:15am EDT

Item 5.02. Departure of Directors or Certain Officers; Election of Directors.

On June 14, 2021, Forma Therapeutics Holdings, Inc. (the "Company") announced the appointment of John Bishop, Ph.D., as Chief Technology Officer of the Company, effective June 14, 2021 (the "Effective Date"). In connection with Dr. Bishop's appointment, the Company has entered into an employment agreement with Dr. Bishop, dated May 28, 2021 (the "Employment Agreement"), pursuant to which Dr. Bishop will serve as Chief Technology Officer of the Company, effective as of the Effective Date. The Employment Agreement, which is in the same form as its standard form of employment agreement with the Company's other executive officers, provides for "at will" employment and entitles Dr. Bishop to an annual base salary of $425,000 and an initial one-time signing bonus of $165,000. Dr. Bishop is also eligible for annual incentive compensation targeted at 40% of his base salary. Dr. Bishop is eligible to participate in the employee benefit plans generally available to full-time employees, subject to the terms of those plans.

Pursuant to the Employment Agreement, if Dr. Bishop's employment is terminated by the Company without cause or by Dr. Bishop for good reason within three months prior to and in connection with the closing of a change of control (as such terms are defined in his Employment Agreement and subject to the terms and conditions therein) or the twelve-month period following a change in control, then Dr. Bishop will be entitled to (1) a lump sum cash payment equal to the sum of his then-current annual base salary (or his base salary in effect immediately prior to the change in control, if higher) and his target bonus for the then-current year, (2) full acceleration of all time-based equity awards held by Dr. Bishop, and (3) monthly cash payments equal to the monthly employer contribution that the Company would have made to provide health insurance for Dr. Bishop and any covered dependents until the earliest of (i) the twelve month anniversary of the date of termination, (ii) Dr. Bishop's eligibility for group medical plan benefits under any other employer's group medical plan or (iii) the cessation of Dr. Bishop's continuation rights under Consolidated Omnibus Budget Reconciliation Act (COBRA).

In connection with Dr. Bishop's appointment, the Compensation Committee (the "Compensation Committee") of the Company's board of directors granted Dr. Bishop a stock option to purchase up to 67,000 shares of the Company's common stock. Twenty-five percent of the shares underlying such option shall vest on June 14, 2022 and the remainder of such shares shall vest in thirty-six equal monthly installments thereafter. The Compensation Committee also granted Dr. Bishop 22,000 restricted stock unit awards ("RSUs"). Twenty-five percent of the RSUs shall vest on June 14, 2022 and an additional twenty-five percent of the remaining RSUs shall vest annually on each anniversary of June 14.

Item 7.01. Regulation FD Disclosure.

On June 14, 2021, in connection with Dr. Bishop's appointment as Chief Technology Officer, the Company issued a press release titled "Forma Therapeutics Announces Appointment of Industry Veteran John E. Bishop, Ph.D., as Chief Technology Officer," a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, attached hereto, is intended to be furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Exhibits

(d) Exhibits

99.1      Press release issued by Forma Therapeutics Holdings, Inc. on June 14,
        2021, furnished herewith.


© Edgar Online, source Glimpses

09/17FORMA THERAPEUTICS : to Participate in Upcoming Investor Conferences
08/17FORMA THERAPEUTICS : HC Wainwright Adjusts Price Target on Forma Therapeutics Ho..
08/13FORMA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
08/13FORMA THERAPEUTICS' : Q2 Loss Narrows, Operating Expenses Rise
08/13FORMA THERAPEUTICS HOLDINGS, INC. : Results of Operations and Financial Conditio..
08/13FORMA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides ..
08/13Forma Therapeutics Holdings, Inc. Reports Unaudited Consolidated Earnings Res..
08/06FORMA THERAPEUTICS : to Report Second Quarter 2021 Financial Results and Provide..
08/02FORMA THERAPEUTICS : Craig-Hallum Starts Forma Therapeutics Holdings at Buy With..
More news
Analyst Recommendations on FORMA THERAPEUTICS HOLDINGS, INC.
More recommendations